Le Lézard
Classified in: Health, Science and technology

HELIX Life Sciences Launches a New Collaboration Platform and Brand Initiative

SAN FRANCISCO, July 13, 2018 /PRNewswire-PRWeb/ -- HELIX Life Sciences, a leading provider of life sciences collaboration solutions and services, today announced it has launched it's latest drug development collaboration platform, HELIX Coretm.

"We are very pleased to announce the launching of HELIX Core. HELIX Core is the culmination of years of experience with a broad spectrum of life sciences companies ? 12 Beta customers in total, all striving to bring innovations to their market in a more efficient and compliant way," said Amber Bahl, HELIX's CEO. "I'm extremely proud of the HELIX team we've assembled to spearhead this launch. These are seasoned life science and IT professionals, armed with proven processes, technical expertise and amazing insight into how the process of developing pharmaceutical products can be optimized via seamless and advanced collaboration," said Bahl.

HELIX Core empowers teams to closely and effectively collaborate on work items and documentation throughout the drug development cycle. Being purpose-built for life sciences teams, HELIX requires no upfront software development process and can be implemented in a matter of days.

"Our goal is to disrupt the current collaboration market with industry-specific applications ? solutions that offer comprehensive, out-of-the-box functionality at a fraction of the cost of conventional platforms offered by today's vendors," continued Bahl. "For Life Sciences organizations, HELIX represents a significantly faster, more economical way to empower their teams ? along with an increased ability to maintain compliance requirements across their parallel and complex projects."

HELIX is the latest company to be spun off by San Francisco's Cyclotron Group (http://www.cyclotrongroup.com) ?a global IT and technology development company focused on creating industry-specific collaboration empowerment solutions.

"We're also excited about launching HELIX's new brand initiative via our latest website," said Bahl. "We've gotten excellent feedback on the platform from our Beta users. They concur that our disruptive positioning in the marketplace is a more powerful, and significantly cheaper, way to foster accelerated drug development via cloud-based, purpose-built collaboration solutions," concluded Bahl.

About HELIX for Life Sciences
HELIX Life Sciences' focus is to create a new standard of drug development collaboration efficiency and compliance. HELIX Coretm ships with multiple modules all centered around collaboration for drug discovery and development. HELIX Core is the first component of the platform. Planned additions to HELIX include purpose-built modules for Commercial, QA, Clinical ? GxP, and Non-GxP. Headquartered in San Francisco, HELIX was founded in 2017, and currently has over 50 employees in the US and Asia. HELIX is a part of the Cyclotron Group of companies. For more information, visit the company's website at http://www.HelixLifeSciences.com


SOURCE HELIX for Life Sciences

These press releases may also interest you

at 17:36
Grown Rogue International Inc. (formerly Novicius Corp.) ("Grown Rogue" or the "Company"), is pleased to announce that it has closed its previously announced reverse takeover transaction (the "Transaction") with Grown Rogue Unlimited, LLC ("Grown...

at 17:35
Aquestive Therapeutics, Inc. today announced it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) in regards to its New Drug Application (NDA) for tadalafil oral film (OF). Tadalafil is a PDE5 inhibitor...

at 17:33
Last month, the U.S. Department of Agriculture and the U.S. Food and Drug Administration held a public meeting to discuss the use of livestock and poultry cell lines to develop cell-cultured food products. At this meeting, stakeholders shared...

at 17:32
The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by...

at 17:28
A 'first' as far as CBD bioaccessibility research goes, using the same scientifically proven method many pharmaceutical companies use, the TIM-1 test is a dynamic model of the upper gastrointestinal tract simulating fasted state conditions. Results...

at 17:00
DELRAY BEACH, Fla., Nov. 16, 2018 /PRNewswire-PRWeb/ -- Specialty MED Training, a subsidiary of Swartz Marketing Group, relocated to the 401-building inside the TED Center complex located in the heart of Delray Beach, Florida. TED, which stands for...

News published on 13 july 2018 at 23:00 and distributed by: